I-Mab
Fusion Proteins Containing CD47 Antibodies and Cytokines

Last updated:

Abstract:

The present invention provides fusion proteins containing cytokines and novel CD47 antibodies or immunologically active fragments thereof, as well as pharmaceutical compositions containing such fusion proteins that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation. These fused proteins have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination.

Status:
Application
Type:

Utility

Filling date:

12 Nov 2018

Issue date:

1 Apr 2021